Real-world outcomes of mosunetuzumab use in indolent and aggressive lymphomasAndrew Jallouk, Sairah Ahmed, Lorenzo Falchi et al.|Blood|2025Cited by 0
Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphomaPierre Stéphan, Jennifer L. Crombie, Shannon M. Buckley et al.|Blood|2025Cited by 0
Evaluation of prognostic factors and survival outcomes in patients with Relapsed/Refractory (R/R) large B-cell lymphomas (LBCLs) treated with epcoritamabAllison M. Bock, Sairah Ahmed, Lei Feng et al.|Blood|2025Cited by 0
Performance Status Outperforms Comorbidities As Predictor of Survival after Bsabs for Large B cell LymphomaGeoffrey Shouse, Ayushi Chauhan, Jomel Meeko Manzano et al.|Transplantation and Cellular Therapy|2026Cited by 0
Outcomes of Bispecific Antibody Treatment of Double Hit Lymphoma, a Real-World Evidence (RWE) StudyGeoffrey Shouse, Gulrayz Ahmed, Sairah Ahmed et al.|Transplantation and Cellular Therapy|2026Cited by 0